DLL3 and small cell lung carcinoma: Although the DLL3-targeting antibody-drug conjugate (ADC) drug rovalpituzumab tesirine (Rova-T) has not been shown to be superior to topotecan in OS in patients with relapsed and/or recurrent SCLC (101), the DLL3-targeting bispecific T-cell engager Tarlatamab effectively promoted regression of SCLC tumors and liver metastases in mouse models (102).